A review of progress on complement and primary membranous nephropathy

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• Primary membranous nephropathy (PMN) is a major cause of adult nephrotic syndrome, with increasing incidence and significant progression to renal failure.
• The complement system, including classical, mannose-binding lectin, and alternative pathways, plays a crucial role in PMN pathogenesis.
• Recent evidence confirms the involvement of the classical complement pathway in PMN, despite historical detection challenges.

Purpose of the Study:

• To review recent research on the complement pathway's role in primary membranous nephropathy pathogenesis.
• To highlight the therapeutic potential of complement inhibitors in managing PMN.
• To emphasize the need for continued research in complement-targeted therapies for PMN.

Main Methods:

• Literature review of recent studies on complement pathways in PMN.
• Analysis of current clinical trials evaluating complement inhibitors for PMN.
• Synthesis of evidence regarding complement dysregulation in PMN.

Main Results:

• All three complement activation pathways are implicated in PMN pathogenesis.
• The classical pathway is confirmed to be involved in PMN.
• Multiple complement inhibitors targeting various components (MASP2, C3/C3b, FD, C3aR, FB) are under clinical investigation.

Conclusions:

• Dysregulation of the complement system is central to PMN.
• Complement inhibitors represent a promising therapeutic strategy for PMN.
• Further research into complement pathways and inhibitors is crucial for advancing PMN treatment and improving patient outcomes.